Symbicort Turbohaler
Symbicort Turbohaler is a combination inhaler used to treat asthma in adults and children aged 6 years and older. It contains two active ingredients: budesonide, a corticosteroid that reduces inflammation in the lungs, and formoterol, a long-acting bronchodilator that relaxes the airway muscles. It can be prescribed in two ways: as a daily preventer with a separate reliever, or as a single inhaler for both maintenance and relief therapy (MART), helping to control and prevent asthma symptoms.
Complete a short online consultation so our prescriber can confirm the treatment suits you.
The decision to supply the specific treatment and quantity requested will be based on whether our medical team are satisfied that it will be safe, appropriate, and effective.
Or 3 interest-free payments of £16.53 via Klarna
Tracked 24 Delivery3 interest-free payments via KlarnaDiscreet packaging
Symbicort Treatment
| Product Name | Symbicort |
| Manufacturer | AstraZeneca |
| Active Ingredient | Budesonide & Formoterol fumarate dihydrate |
| Administration | Oral Inhalation |
| Presentation | Dry Powder Inhaler (Turbohaler) |
| Available Strengths | 100/6 / 120 Doses |
| Product Type | POM — Prescription Only |
| Dosage | CONFIRM DEVICE/PLAN: Proposed maintenance dose is ONE or TWO inhalations twice daily. Confirm device, exact dose and maintenance-only versus MART. Rinse and spit after maintenance doses. |
| Suitable for pregnancy? | Caution |
| Use with alcohol | No known interaction |
| Link to Patient Information Leaflet | Symbicort PIL ↗ |
Medical Content Officer
Nabeel is a co-founder, and medical content officer of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Talal is a GMC registered doctor and medical content reviewer at Chemist Doctor. He ensures clinical accuracy and reliability across health content.
Medical Administrative Officer
Usman is a co-founder, and medical administrative officer of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical administration and operational priorities.
Review Date: 2 Jul 2026
Next Review: 1 Jan 2027
Published on: 19 Nov 2025
Last Updated: 3 Jul 2026
